New England Research & Management, Inc. Regeneron Pharmaceuticals, Inc. Transaction History

New England Research & Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 05, 2023	BUY	$700.03 - $830.35 $658,028 - $780,529	940 New	940 $675,000
Q3 2022 Oct 06, 2022	SELL	$573.97 - $724.32 $33,864 - $42,734	-59 Reduced 5.95%	932 $642,000
Q2 2022 Jul 20, 2022	BUY	$548.35 - $738.84 $24,675 - $33,247	45 Added 4.76%	991 $586,000
Q1 2022 Apr 20, 2022	SELL	$595.12 - $698.43 $17,258 - $20,254	-29 Reduced 2.97%	946 $661,000
Q4 2021 Jan 05, 2022	BUY	$543.48 - $670.97 $195,652 - $241,549	360 Added 58.54%	975 $616,000
Q3 2021 Oct 08, 2021	SELL	$574.03 - $680.96 $599,861 - $711,603	-1,045 Reduced 62.95%	615 $372,000
Q2 2021 Jul 15, 2021	SELL	$472.8 - $558.54 $94,560 - $111,708	-200 Reduced 10.75%	1,660 $927,000
Q1 2021 Apr 16, 2021	BUY	$446.73 - $548.2 $323,879 - $397,445	725 Added 63.88%	1,860 $880,000
Q4 2020 Jan 07, 2021	SELL	$478.3 - $607.98 $224,801 - $285,750	-470 Reduced 29.28%	1,135 $548,000
Q3 2020 Oct 08, 2020	BUY	$544.75 - $658.21 $874,323 - $1.06 Million	1,605 New	1,605 $898,000

1,484

83.7M

1.22M

1.5M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of New England Research & Management, Inc., based on Form 13F filings with the SEC.

Stay updated on New England Research & Management, Inc. with notifications on news.